\
&
Contact us
\
&
Contact us
This was 1 year ago
LocationOnline
ProgrammesThe European Health and Digital Executive Agency (HaDEA) organises an online info session on Digital Europe call DIGITAL-2024-BESTUSE-TECH-07-EDMO - European Digital Media Observatory.
The European Digital Media Observatory (EDMO) has been created with the aim of supporting an independent multidisciplinary community to tackle the phenomenon of disinformation. EDMO is composed of the regional hubs and a central platform and governance structure which supports and coordinates them.
The objective of this topic is to finance the work of independent regional hubs for analysis of digital media ecosystems in order to ensure the coverage of geographical areas covered by the EDMO hubs for which the funding is ending at the end of 2024 and in 2025.
A hub involves organisations active in one or several Member State(s), that will provide specific knowledge of local information environments so as to strengthen the detection and analysis of disinformation campaigns, improve public awareness, and design effective responses relevant for national audiences. The activities of the hubs are carried out in full independence from third-party entities including public authorities.
More information on the event and the link to participate can be found on the event website.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
